
December 31, 2026

December 31, 2026
먼저 마켓을 선택하세요
왼쪽 목록에서 마켓을 선택하면 여기에 호가창과 거래 패널이 표시됩니다.
왼쪽에서 마켓을 선택하면 표시됩니다.
현재 「December 31, 2026」 40%로 선두 (1주 전 53%). 총 거래량 $5K, 최근 24시간 $30. 유동성 $177. 2026. 12. 31.(미 동부시간) 마감 예정.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
현재 「December 31, 2026」 40%로 선두 (1주 전 53%). 총 거래량 $5K, 최근 24시간 $30. 유동성 $177. 2026. 12. 31.(미 동부시간) 마감 예정.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.